首页> 外国专利> 6-PHENOXYMETHYL-4-HYDROXYTETRAHYDROPYRAN-2-ONE METHOD FOR THE PRODUCTION THEREOF OF ITS USE AS A MEDICAMENT PHARMACEUTICAL PRAPARATES AND INTERMEDIATE PRODUCTS

6-PHENOXYMETHYL-4-HYDROXYTETRAHYDROPYRAN-2-ONE METHOD FOR THE PRODUCTION THEREOF OF ITS USE AS A MEDICAMENT PHARMACEUTICAL PRAPARATES AND INTERMEDIATE PRODUCTS

机译:生产6-6-苯甲基-4-羟基四氢吡喃-2-酮的方法用作药物,医药中间体和中间体

摘要

1. Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A 6-phenoxymethyl-4-hydroxytetrahydropyran-2-one of the general formula I see diagramm : EP0216127,P57,F1 in which R**1 and R**5 are identical or different and denote a) halogen, b) cycloalkyl having 4-8 carbon atoms, or a phenyl radical which can be substituted in the nucleus once to 3 times by halogen, trifluoromethyl, and/or alkyl or alkoxy each having 1-4 carbon atoms, or c) a straight-chain or branched alkyl radical having 1 to 18 carbon atoms, or a straight-chain or branched alkenyl radical having 2 to 18 carbon atoms, it being possible for the alkyl and alkenyl radicals in turn to be substituted 1-3 times by alpha) straight-chain or branched alkoxy radicals having up to 10 carbon atoms, or cycloalkyl radicals having 3 to 7 carbon atoms, or straight-chain or branched alkenyloxy or alkynyloxy radicals having 3 to 6 carbon atoms, beta) halogen, hydroxyl, cycloalkyl having 3-7 carbon atoms, unsubstituted phenyl or alpha- or beta-thienyl radicals, or phenyl or alpha- or beta-thienyl radicals which in turn are substituted in the nucleus once to 3 times by halogen, trifluoromethyl and/or alkyl or alkoxy having 1-4 carbon atoms, gamma) unsubstituted phenoxy, benzyloxy, alpha- or beta-thienyloxy radicals, or phenoxy, benzyloxy, alpha- or beta-thienyloxy radicals which in turn are substituted in the nucleus once to 3 times by halogen, trifluoromethyl and/or alkyl or alkoxy having 1 to 4 carbon atoms, delta) the group see diagramm : EP0216127,P57,F2 R**6 denoting : a straight-chain or branched alkyl or alkenyl radical having up to 8 carbon atoms, or a cycloalkyl or cycloalkenyl radical each having 3-8 carbon atoms, or an unsubstituted phenyl radical, or a phenyl radical which in turn is substituted in the nucleus once to 3 times by halogen, trifluoromethyl and/or alkyl or alkoxy having 1-4 carbon atoms, or a 3-pyridyl radical, R**2 and R**4 denote hydrogen, and R**3 is alkyl or alkenyl having up to 4 carbon atoms, halogen or alkoxy having 1-4 carbon atoms, and the corresponding open-chain dihydroxy carboxylic acid, their pharmacologically tolerated salts with bases, and their pharmacologically tolerated esters. 1. Claims for the Contracting State : AT A process for the preparation of a 6-phenoxymethyl-4-hydroxytetrahydropyran-2-one of the general formula I see diagramm : EP0216127,P62,F1 in which R**1 and R**5 are identical or different and denote a) halogen, b) cycloalkyl having 4-8 carbon atoms, or a phenyl radical which can be substituted in the nucleus once to 3 times by halogen, trifluoromethyl and/or alkyl or alkoxy each having 1-4 carbon atoms, or c) a straight-chain or branched alkyl radical having 1 to 18 carbon atoms, or a straight-chain or branched alkenyl radical having 2 to 18 carbon atoms, it being possible for the alkyl and alkenyl radicals in turn to be substituted 2-3 times by alpha) straight-chain or branched alkoxy radicals having up to 10 carbon atoms, or cycloalkoxy radicals having 3 to 7 carbon atoms, or straight-chain or branched alkenyloxy or alkynyloxy radicals having 3 to 6 carbon atoms, beta) halogen, hydroxyl, cycloalkyl having 3-7 carbon atoms, unsubstituted phenyl or alpha- or beta-thienyl radicals, or phenyl or alpha- or beta-thienyl radicals which in turn are substituted in the nucleus once to 3 times by halogen, trifluoromethyl and/or alkyl or alkoxy having 1-4 carbon atoms, gamma) unsubstituted phenoxy, benzyloxy, alpha- or beta-thienyloxy radicals, or phenoxy, benzyloxy, alpha- or beta-thienyloxy radicals which in turn are substituted in the nucleus once to 3 times by halogen, trifluoromethyl and/or alkyl or alkoxy having 1 to 4 carbon atoms, delta) the group see diagramm : EP0216127,P62,F2 R**6 denoting : a straight-chain or branched alkyl or alkenyl having up to 8 carbon atoms, or a cycloalkyl or cycloalkenyl radical each having 3-8 carbon atoms, or an unsubstituted phenyl radical, or a phenyl radical which in turn is substituted in the nucleus once to 3 times by halogen, trifluoromethyl and/or alkyl or alkoxy having 1-4 carbon atoms, or a 3-pyridyl radical, R**2 and R**4 denote hydrogen, and R**3 is alkyl or alkenyl having up to 4 carbon atoms, halogen or alkoxy having 1-4 carbon atoms, and the corresponding open-chain dihydroxy carboxylic acid, their pharmacologically tolerated salts with bases, and their pharmacologically tolerated esters, which comprises a) conversion of an appropriately substituted phenol of the formula II see diagramm : EP0216127,P62,F3 in which R**1 , R**2 , R**3 , R**4 and R**5 have the indicated meanings, with the chiral iodide of the formula III see diagramm : EP0216127,P63,F1 in which R**10 denotes a protective group which is stable to bases and weak acids, into an ether of the formula IV see diagramm : EP0216127,P63,F2 in which R**1 to R**5 have the meanings indicated for formula I and R**10 has the meanings indicated for formula III, b) hydrolysis of the ether of the formula IV to give the corresponding hemiacetal of the formula V see diagramm : EP0216127,P63,F3 in which R**1 to R**5 and R**10 have the meanings indicated for formula I or III, c) oxidation of the hemiacetal of the formula V to give the corresponding lactone of the formula VI see diagramm : EP0216127,P64,F1 in which R**1 to R**5 have the meanings indicated for formula I and R**10 has the meanings indicated for formula III, and d) conversion of the protected hydroxylactone of the formula VI into the 6-phenoxymethyl-4-hydroxytetrahydropyran-2-one of the formula I see diagramm : EP0216127,P64,F2 where appropriate the compound of the formula I which has been obtained being converted into the corresponding open-chain dihydroxy carboxylic acid of the formula VII see diagramm : EP0216127,P64,F3 its salt or its ester, where appropriate a salt or ester which has been obtained being converted into the free dihydroxy carboxylic acid or, where appropriate, the free carboxylic acid being converted into the salt or ester.
机译:1.对缔约国的索赔:BE,CH,DE,FR,GB,IT,LI,LU,NL,SE A通式为6的苯氧基甲基-4-羟基四氢吡喃-2-酮参见示意图:EP0216127,P57 ,其中R ** 1和R ** 5相同或不同的F1表示a)卤素,b)具有4-8个碳原子的环烷基,或可在原子核中被卤素取代1-3次的苯基,三氟甲基和/或分别具有1-4个碳原子的烷基或烷氧基,或c)具有1至18个碳原子的直链或支链烷基或具有2至18个碳原子的直链或支链烯基,烷基和烯基可能依次被1-3个碳原子数最多10个的直链或支链烷氧基,或碳原子数为3至7个的环烷基或直链取代1-3次或具有3至6个碳原子的支链烯氧基或炔基氧基,β)卤素,羟基,具有3至7个碳原子的环烷基,未取代苯基或α-或β-噻吩基,或苯基或α-或β-噻吩基,它们在原子核中被卤素,三氟甲基和/或具有1-4个碳原子的烷基或烷氧基取代1-3次,γ )未取代的苯氧基,苄氧基,α-或β-噻吩氧基,或苯氧基,苄氧基,α-或β-噻吩氧基,其在原子核中被卤素,三氟甲基和/或具有1的烷基或烷氧基取代1-3次碳原子数至4的碳原子,δ)基团见图:EP0216127,P57,F2 R ** 6表示:具有至多8个碳原子的直链或支链烷基或烯基,或各自具有3-的环烷基或环烯基8个碳原子,或未取代的苯基,或在原子核中被卤素,三氟甲基和/或具有1-4个碳原子的烷基或烷氧基取代1-3次的苯基,或3-吡啶基, R ** 2和R ** 4表示氢,并且R ** 3是烷基或烯基最多包含4个碳原子,具有1-4个碳原子的卤素或烷氧基,以及相应的开链二羟基羧酸,其与碱的药理耐受性盐以及其药理学耐受的酯。 1.缔约国的权利要求:AT一种制备通式为I的6-苯氧基甲基-4-羟基四氢吡喃-2-酮的方法,参见示意图:EP0216127,P62,F1,其中R ** 1和R ** 5相同或不同,表示a)卤素,b)具有4-8个碳原子的环烷基或可在原子核中被卤素,三氟甲基和/或烷基或烷氧基分别取代1-3次的苯基基团4个碳原子,或c)具有1至18个碳原子的直链或支链烷基或具有2至18个碳原子的直链或支链烯基,烷基和链烯基又可以被α)取代2-3次)具有至多10个碳原子的直链或支链的烷氧基,或具有3至7个碳原子的环烷氧基,或具有3至6个碳原子的直链或支链的烯氧基或炔氧基, β)卤素,羟基,具有3-7个碳原子的环烷基,未取代的phe n或α-或β-噻吩基,或苯基或α-或β-噻吩基,它们在核中被卤素,三氟甲基和/或具有1-4个碳原子的烷基或烷氧基取代1-3次,γ )未取代的苯氧基,苄氧基,α-或β-噻吩氧基,或苯氧基,苄氧基,α-或β-噻吩氧基,其在原子核中被卤素,三氟甲基和/或具有1的烷基或烷氧基取代1-3次碳原子数至4的碳原子,δ)基团见图:EP0216127,P62,F2 R ** 6表示:具有至多8个碳原子的直链或支链烷基或烯基,或各自具有3-8个碳原子的环烷基或环烯基碳原子,或未取代的苯基,或在原子核中被卤素,三氟甲基和/或具有1-4个碳原子的烷基或烷氧基取代1-3次的苯基,或3-吡啶基,R ** 2和R ** 4表示氢,并且R ** 3是具有至多4个的烷基或烯基碳原子,具有1-4个碳原子的卤素或烷氧基,以及相应的开链二羟基羧酸,其与碱的药理学上允许的盐以及其药理学上允许的酯,包括a)适当取代的式II酚的转化参见示意图:EP0216127,P62,F3,其中R ** 1,R ** 2,R ** 3,R ** 4和R ** 5具有所示含义,式III的手性碘化物见图: EP0216127,P63,F1,其中R ** 10表示对碱和弱酸稳定的保护基,对于式IV的醚,请参见示意图:EP0216127,P63,F2,其中R ** 1至R ** 5具有式I所示的含义,R ** 10具有式III所示的含义b)将式IV的醚水解以得到相应的式V的半缩醛,参见图:EP0216127,P63,F3,其中R ** 1至R ** 5和R ** 10具有对于式所示的含义。 I或III,c)将式V的半缩醛氧化以得到相应的式VI的内酯,参见图:EP0216127,P64,F1,其中R ** 1至R ** 5具有式I和R所示的含义。 R ** 10具有对于式III所指示的含义,并且d)将式VI的被保护的羟基内酯转化为式I的6-苯氧基甲基-4-羟基四氢吡喃-2-酮,见图:EP0216127,P64,F2合适地,将所获得的式I化合物转化为相应的式VII的开链二羟基羧酸,参见图:EP0216127,P64,F3,其盐或酯,在适当情况下,已获得的盐或酯被转化为游离的二羟基羧酸,或例如,游离羧酸被转化为盐或酯。

著录项

  • 公开/公告号PT83270A

    专利类型

  • 公开/公告日1986-09-01

    原文格式PDF

  • 申请/专利权人 HOECHST AKTIENGESELLSCHAFT;

    申请/专利号PT19860083270

  • 发明设计人

    申请日1986-08-28

  • 分类号C07D309/30;A61K31/35;

  • 国家 PT

  • 入库时间 2022-08-22 07:40:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号